Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 18835619)

1.

Diagnosis of prostatic neuroendocrine carcinoma: Two cases report and literature review.

He HQ, Fan SF, Xu Q, Chen ZJ, Li Z.

World J Radiol. 2015 May 28;7(5):104-9. doi: 10.4329/wjr.v7.i5.104.

2.

A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells.

Ding M, Lin B, Li T, Liu Y, Li Y, Zhou X, Miao M, Gu J, Pan H, Yang F, Li T, Liu XY, Li R.

Oncotarget. 2015 Apr 10;6(10):7686-700.

3.

Neuroendocrine differentiation of prostate cancer: a review.

Parimi V, Goyal R, Poropatich K, Yang XJ.

Am J Clin Exp Urol. 2014 Dec 9;2(4):273-85. eCollection 2014. Review.

4.

An ultra scale-down analysis of the recovery by dead-end centrifugation of human cells for therapy.

Delahaye M, Lawrence K, Ward SJ, Hoare M.

Biotechnol Bioeng. 2015 May;112(5):997-1011. doi: 10.1002/bit.25519. Epub 2015 Mar 12.

5.

SOX2 expression in the developing, adult, as well as, diseased prostate.

Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, Hayward SW, Matusik RJ.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):301-9. doi: 10.1038/pcan.2014.29. Epub 2014 Aug 5.

6.

Aggressive variants of castration-resistant prostate cancer.

Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA.

Clin Cancer Res. 2014 Jun 1;20(11):2846-50. doi: 10.1158/1078-0432.CCR-13-3309. Epub 2014 Apr 11. Review.

7.

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.

Lipianskaya J, Cohen A, Chen CJ, Hsia E, Squires J, Li Z, Zhang Y, Li W, Chen X, Xu H, Huang J.

Asian J Androl. 2014 Jul-Aug;16(4):541-4. doi: 10.4103/1008-682X.123669.

8.

A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children.

Liu Z, Zhao X, Wang Y, Mao H, Huang Y, Kogiso M, Qi L, Baxter PA, Man TK, Adesina A, Su JM, Picard D, Ching Ho K, Huang A, Perlaky L, Lau CC, Chintagumpala M, Li XN.

Neuro Oncol. 2014 Jun;16(6):787-99. doi: 10.1093/neuonc/not244. Epub 2014 Jan 26.

9.

Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ, Liu W, Isaacs WB, De Marzo AM, Lotan TL.

Clin Cancer Res. 2014 Feb 15;20(4):890-903. doi: 10.1158/1078-0432.CCR-13-1982. Epub 2013 Dec 9.

10.

Review of small cell carcinomas of the prostate.

Furtado P, Lima MV, Nogueira C, Franco M, Tavora F.

Prostate Cancer. 2011;2011:543272. doi: 10.1155/2011/543272. Epub 2011 Aug 4.

11.

ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.

Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, Osunkoya AO, MacLennan GT, Montironi R, Cheng L.

Mod Pathol. 2011 Aug;24(8):1120-7. doi: 10.1038/modpathol.2011.56. Epub 2011 Apr 15.

12.

PC3 is a cell line characteristic of prostatic small cell carcinoma.

Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J.

Prostate. 2011 Nov;71(15):1668-79. doi: 10.1002/pros.21383. Epub 2011 Mar 22.

14.

Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.

Yang K, Tang Y, Habermehl GK, Iczkowski KA.

BMC Cancer. 2010 Jan 14;10:16. doi: 10.1186/1471-2407-10-16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk